Opaleye Management’s Insmed INSM Stock Holding History

Opaleye Management’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-120,000	Closed	-$3.75M	–	38
2017 Q3	$3.75M	Buy	+120,000	New	+$2.29M	1.32%	25

Other funds holding INSM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Opaleye Management's INSM Position: Q4 2017 in Review

Opaleye Management sold out of Insmed (INSM) in Q4 2017, closing a stake of 120,000 shares — an estimated $3.75M sold.

Opaleye Management first reported a position in INSM in Q3 2017 and held it in 1 quarter. The position peaked at $3.75M in Q3 2017. 129 funds tracked by Wall St. Rank hold INSM as of Q4 2017.

Opaleye Management reported no remaining Insmed position as of Q4 2017 after selling out during the quarter.
Opaleye Management sold 120,000 Insmed shares in Q4 2017, an estimated $3.75M.
Opaleye Management first reported a position in Insmed in Q3 2017 and held it in 1 quarter.
Opaleye Management's Insmed position peaked at $3.75M in Q3 2017.
129 funds tracked by Wall St. Rank held Insmed as of Q4 2017.

Based on Opaleye Management's 13F filing for Q4 2017, filed 9 Feb 2018.